Stocktoria
Edgewise Therapeutics, Inc. EWTX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-03-26
Edgewise Therapeutics, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| R&D expense | $151.4M | $127.0M | $90.9M | $54.0M | $32.2M | $15.0M |
| Operating income | -$191.4M | -$158.8M | -$114.4M | -$71.7M | -$43.2M | -$17.2M |
| Income tax | $4,000 | $3,000 | $4,000 | $0 | $0 | — |
| Net income | -$167.8M | -$133.8M | -$100.2M | -$67.6M | -$42.8M | -$17.1M |
| EPS (diluted) | $-1.63 | $-1.45 | $-1.57 | $-1.26 | $-1.14 | $-23.17 |
| Operating cash flow | -$143.8M | -$109.0M | -$91.9M | -$52.6M | -$33.5M | -$14.6M |
| Free cash flow | -$144.1M | -$110.3M | -$97.7M | -$58.2M | -$34.2M | -$14.8M |
| Cash & equivalents | $61.1M | $41.7M | $86.1M | $22.0M | $15.6M | $104.9M |
| Total assets | $552.6M | $486.8M | $340.0M | $367.1M | $285.2M | $131.1M |
| Total liabilities | $30.3M | $27.6M | $21.2M | $20.4M | $10.8M | $4.3M |
| Shareholders' equity | $522.3M | $459.2M | $318.8M | $346.7M | $274.4M | -$33.4M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.